On October 26th, 2015 PharmaMar reported that for the next few days, thousands of oncology experts in gynecologic cancers are gathering during the 19th Biennial Meeting of the European Society of Gynecological Oncology (ESGO 2015), which is taken place from October 24-27, 2015 in Nice, France. ESGO is the European leading organization that aims to advance gynecologic cancer care and is strongly committed to help women in Europe with this disease. This forum is an excellent opportunity for clinicians, researchers, patient associations and drug developers to learn about the most exciting developments in the field of gynecologic cancers, which include ovarian, cervical, uterine, vaginal and vulvar cancers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The initial standard treatment for ovarian cancer implies a platinum-based combination therapy. However, after recurrence, leading oncologists in the field recommend evaluating patients on a case-by-case basis to identify the best therapeutic option for each patient. In this scenario, platinum-free therapies keep gaining traction among clinicians.
"Making the most of every option in the treatment of ovarian cancer. Choosing the optimal sequency" is the title of the satellite symposium organized by PharmaMar, which gathered more than 600 oncologists, during ESGO 2015 to bring together
national and international oncologists and discuss the different aspects that need to be considered from a clinical standpoint to treat women with recurrent ovarian cancer. Among the most crucial topics to be discussed are the best approaches to
manage and overcome platinum hypersensitivity and the clinical benefit of platinum-free therapies after recurrence.
One of the participants, Nicoletta Colombo, MD, European Oncology Institute, University of Milan-Bicocca, Milan, has pointed how certain platinum sensitive tumors can also respond to other therapies and said "among the benefits of switching from a platinum-based therapy to a non-platinum treatment you can find two important aspects of the management of these patients; the probable recovery from neurotoxicity that is associated to platinum, and the potential to reduce and even prevent the hipersensitivity often found during treatment of these women with platinum".
When a patient is partially sensitive to platinum, that is the patient relapses within 6 to 12 months after treatment with platinum, among the recommended therapeutic options, oncologists and the most recent ESMO (Free ESMO Whitepaper) Clinical Practice Guidelines suggest a treatment combining YONDELIS (trabectedin) with pegylated liposomal doxorubicin followed by a platinum-based therapy. Dr. Colombo explained that with this sequential treatment, an overall survival of 6 months and a 41 percent reduction in the risk of death can be obtained. Also, the treated patient can recover from the toxicity caused by platinum-based therapiesi". The hypothesis to explain the benefit of this sequential treatment is that such approach could enhance the sensitivity of the tumor to a next platinum therapy, thus increasing the survival of the patient.
Studies highlighted at ESGO 2015
PharmaMar introduces several posters to show clinical data about the treatment combining YONDELIS with PLD in different patient profiles.
YONDELIS (trabectedin)
Complete response to trabectedin in combination with pegylated liposomal doxorubicin (PLD) in heavily pre-treated BRCA-2 mutated platinum-sensitive intermediate epithelial ovarian cancer (EOC)
Poster: Saturday 24th, October, e-poster station
Lead author: P. Biondani, Hôpital Tenon 4 Rue de la chine 75020 Paris
BRCA mutated ovarian cancer complete remission following second line treatment with trabectedin and lposomal Adriamycin
Poster: Saturday 24th, October, e-poster station
Lead author: Dr. Raffaella Bracci, Clinica di Oncologia Medica
Centro Regionale Genetica Oncologica, Azienda Ospedaliero-Universitaria
Ospedali Riuniti, Italy
Extending the platinum-free interval (PFI) with trabectedin plus pegylated liposomal doxorubicin (PLD) in a patient with partially
platinum-sensitive (PPS) recurrent ovarian cancer (ROC)
Poster: Saturday 24th, October, e-poster station
Lead autor: Dr.ssa Sara Giovannoni, U.O.C.Oncologia B, Policlinico Umberto
I Roma
Long-lasting complete response with trabectedin plus pegylated liposomal doxorubicin (PLD) in a young BRCA-mutated woman with platinum-sensitive relapsed ovarian cancer (ROC): a case report
Poster: Saturday 24th, October, e-poster station
Lead autor: Dr.ssa Sara Giovannoni, U.O.C.Oncologia B, Policlinico Umberto
I Roma
Prolonged treatment with trabectin plus pegylated liposomal doxorubicin (PLD) combination in a heavily pretreated patient with
metastatic relapsed ovarian cancer (ROC)
Poster: Saturday 24th, October, e-poster station
Lead author: Dr Pierre Guillet, Centre Hospitalier Sainte Musse, Toulon
Trabectedin in combination with pegylated liposomal doxorubicin to treat heavily-treated patient with relapsed ovarian cancer
Poster: Saturday 24th, October, e-poster station
Lead author: Professor Dr Saad Tahir. Broomfield Hospital. Chelmsford
Trabectedin in monoteraphy, a therapeutic option
Poster: Saturday 24th, October, e-poster station
Lead autor: Dr S. Rego, Hospital da Arrábida, Portugal
METASTATIC OVARIAN CANCER – CHRONIC DISEASE?
Poster: Saturday 24th, October, e-poster station
Lead autor: Dr S. Rego, Hospital da Arrábida, Portugal
Multicenter retrospective study to analyze the effectiveness and safety of trabectedin (T) + PLD in recurrent ovarian cancer (ROC)
patients according to SMPC. GEICO-1402r study
Poster: Saturday 24th, October, e-poster station
Lead author: Dr L. Vidal, Hospital Universitari Clinic de Barcelona
Trabectedin in advanced gynaecological carcinosarcomas – a single institution series (abstract #57)
Poster: Sunday 25th, October, poster area (endometrial cancer)
Laed author: Dr. J. Gounaris, Department of Oncology, Addenbrooke´s
Hospital, Cambridge, UK
PM1183 (lurbinectedina)
The Company also shows another poster about PM1183, a novel transcription inhibitor and DNA repair, to treat relapsed platinum-sensitive ovarian cancer
LURBINECTEDIN (PM01183) EFFICACY IN PLATINUMRESISTANT/REFRACTORY OVARIAN CANCER (PRROC) PATIENTS CORRELATES WITH DRUG EXPOSURE USING
PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELLING
(abstract #157)
Poster: Monday 26th, October, poster area
Lead author: C. Fernandez-Teruel